The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy

The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy Publisher Pubmed

Panahi Y¹ ; Manayi A² ; Nikan M² ; Vazirian M³

Show Affiliations

1. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2. Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3. Pharmacognosy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Biomedicine and Pharmacotherapy Published:2017

Abstract

Glaucoma represents several optic neuropathies leading to irreversible blindness through progressive retinal ganglion cell (RGC) loss. Reduction of intraocular pressure (IOP) is known as the only modifiable factor in the treatment of this disorder. Application of exogenous cannabinoids to lower IOP has attracted attention of scientists as potential agents for the treatment of glaucoma. Accordingly, neuroprotective effect of these agents has been recently described through modulation of endocannabinoid system in the eye. In the present work, pertinent information regarding ocular endocannabinoid system, mechanism of exogenous cannabinoids interaction with the ocular endocannabinoid system to reduce IOP, and neuroprotection property of cannabinoids will be discussed according to current scientific literature. In addition to experimental studies, bioavailability of cannabinoids, clinical surveys, and adverse effects of application of cannabinoids in glaucoma will be reviewed. © 2016 Elsevier Masson SAS

2. Therapeutic Attributes of Endocannabinoid System Against Neuro-Inflammatory Autoimmune Disorders, Molecules (2021)

3. Carbon Nanotubes Prolong the Regulatory Action of Nerve Growth Factor on the Endocannabinoid Signaling, Physiology and Pharmacology (2015)

4. Effects of Cannabinoids and Their Receptors on Viral Infections, Journal of Medical Virology (2016)

5. Endocannabinoids and Related Compounds As Modulators of Angiogenesis: Concepts and Clinical Significance, Cell Biochemistry and Function (2022)

6. Interaction Between the Protective Effects of Cannabidiol and Palmitoylethanolamide in Experimental Model of Multiple Sclerosis in C57bl/6 Mice, Neuroscience (2015)

Experts (# of related papers)

View all Related Experts

Ahmad Reza Dehpour (1)

Farshid Noorbakhsh (1)

Style	Citing Format
MLA	Panahi Y, et al.. "The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy." Biomedicine and Pharmacotherapy, vol. 86, no. , 2017, pp. 620-627.
APA	Panahi Y, Manayi A, Nikan M, Vazirian M (2017). The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy. Biomedicine and Pharmacotherapy, 86(), 620-627.
Chicago	Panahi Y, Manayi A, Nikan M, Vazirian M. "The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy." Biomedicine and Pharmacotherapy 86, no. (2017): 620-627.
Harvard	Panahi Y et al. (2017) 'The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy', Biomedicine and Pharmacotherapy, 86(), pp. 620-627.
Vancouver	Panahi Y, Manayi A, Nikan M, Vazirian M. The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy. Biomedicine and Pharmacotherapy. 2017;86():620-627.
BibTex	@article{ author = {Panahi Y and Manayi A and Nikan M and Vazirian M}, title = {The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy}, journal = {Biomedicine and Pharmacotherapy}, volume = {86}, number = {}, pages = {620-627}, year = {2017} }
RIS	TY - JOUR AU - Panahi Y AU - Manayi A AU - Nikan M AU - Vazirian M TI - The Arguments for and Against Cannabinoids Application in Glaucomatous Retinopathy JO - Biomedicine and Pharmacotherapy VL - 86 IS - SP - 620 EP - 627 PY - 2017 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract